Xinhua Biotech is a leading AI-driven macromolecule drug research and development company, founded in 2019 by a team of senior antibody drug engineering and computational scientists. The company has extensive experience in macromolecule drug research and development along with unique advantages in engineering development data. Its innovative target discovery platform and advanced algorithm platform for antibody structure and engineering have led to significant technological breakthroughs. Currently, the company is focused on addressing unmet medical needs, particularly in tumor immunotherapy, with multiple projects that have demonstrated positive biological verification data.

Xinhua Biology (信华生物)

Xinhua Biology (信华生物)